#United States #New Orleans #blood pressure #Biozen #BP1000

Biozen to Present Revolutionary Cuffless Blood Pressure Measurement at ACC 2026

Biozen, LLC is set to make waves in the medical technology world as it prepares to unveil its groundbreaking cuffless blood pressure device, the BP1000, at the upcoming American College of Cardiology (ACC) Scientific Sessions. Scheduled to take place from March 28 to March 30, 2026, at the Ernest N. Morial Convention Center in New Orleans, this event is a significant platform for showcasing new advancements in cardiovascular health technology.

The presentation is expected to attract considerable attention, as Biozen will share results from a prospective clinical validation study. This extensive study evaluated the performance of the BP1000 against traditional blood pressure measurement methods, which have largely remained unchanged for decades. The validation process adhered to the ISO 81060-2:2018 protocol, a rigorous international standard for assessing non-invasive blood pressure devices, ensuring that the results meet high-quality benchmarks.

In total, 264 participants were involved in the study, which tested the device under conditions that closely mimic real-world scenarios. This prospective evaluation meant that both the device and its algorithms were finalized before the study commenced, with no alterations made during testing to ensure reliable data.

The BP1000 utilizes an innovative combination of pressure sensing, optical sensing, and physiologically-informed algorithms to facilitate direct blood pressure measurement. By occluding the artery at the fingertip, the device eliminates the need for a traditional cuff, making it a more user-friendly option. As Dikran Tourian, CEO of Biozen, points out, “Blood pressure measurement hasn't fundamentally changed in decades. We've built a new way to do it—one that's grounded in physiology without the need for a cuff or calibration.”

Dr. Omer Inan, Chief Scientific Officer at Biozen, highlights that the study’s design mirrors practical use in clinical settings, thus addressing the device's performance comprehensively. Notably, the study placed a significant emphasis on including participants with Fitzpatrick skin types V and VI, as well as individuals categorized under Obesity Class I and II. Historically, monitoring systems have struggled with these demographics, making Biozen's inclusive approach particularly noteworthy.

The implications of this study reach far beyond just numbers and data. Biozen's potential to offer a scalable and physiology-centric blood pressure measurement solution marks a substantial shift in the healthcare sector. It speaks to a growing trend favoring non-invasive technology that is easier to use and potentially more comfortable for patients.

Biozen, headquartered in Oklahoma City with R&D in Atlanta, is a digital health company that holds more than 65 patents worldwide to protect its innovative approaches to health technology. While its devices are still in investigational stages and have not yet received FDA clearance for commercial distribution, the data presented at ACC could pave the way for future approvals and market entry.

In summary, the upcoming presentation at ACC serves as both a milestone for Biozen and a landmark moment for advancements in blood pressure monitoring technologies. As the healthcare landscape continues to evolve, innovations like the BP1000 could play an integral role in improving patient monitoring and outcomes, showcasing how modern technology is reshaping the future of health measurement and management.

For more information on Biozen and its innovative products, interested parties can visit biozen.com.